Role of Noradrenaline in Hepatorenal Syndrome
Mechanism of Action and Efficacy
- Noradrenaline increases mean arterial pressure (MAP) and renal perfusion pressure, which helps improve renal function in HRS patients 1, 3
- Studies comparing noradrenaline with terlipressin have demonstrated noninferiority in reversing HRS-1, with response rates of 39-70% for noradrenaline versus comparable rates for terlipressin 1
- Noradrenaline is administered as a continuous infusion at doses of 0.5-3 mg/h, with the dose titrated to achieve an increase in MAP of at least 10 mmHg above baseline 2
Administration Protocol
- Noradrenaline is typically started at 0.1-0.5 μg/kg/min (7-35 μg/min in a 70-kg adult) and titrated to effect 4
- Administration through a central venous line is preferred to prevent tissue necrosis from extravasation 4
- Noradrenaline should be combined with albumin (1 g/kg on day 1 followed by 20-40 g/day) to optimize efficacy 2, 5
- Treatment should continue until serum creatinine decreases below 1.5 mg/dl or for a maximum of 14 days 6, 7
Advantages Over Other Vasoconstrictors
- In patients with acute-on-chronic liver failure (ACLF), noradrenaline can effectively improve renal function, though terlipressin may be superior in this specific subset 1, 5
Monitoring and Safety Considerations
- Patients should be monitored for changes in MAP, with a target increase of ≥5 mmHg by day 3 of treatment, which predicts a high probability of response 6, 7
- Regular monitoring of renal function is essential, with a decrease in serum creatinine of at least 25% by day 3 indicating a positive response 7, 5
Potential Complications and Precautions
- Noradrenaline is relatively contraindicated in patients with hypovolemia, as it may increase myocardial oxygen requirements 4
Transitioning Between Vasoconstrictors
- When transitioning from noradrenaline to terlipressin, maintain the noradrenaline infusion initially and reduce it gradually while monitoring MAP 5